CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42681803

Asdi Wihandono; Dedy Hermansyah; Febriyanto Kurniawan; Kristanto Yuli Yarso; Prihantono Prihantono; Putu Anda Tusta Adiputra; Samuel J Haryono; Sonar Soni Panigoro; Sumadi Lukman Anwar; Yohana Azhar

Sep 3, 2026